A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Phase Ⅰa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002Following Intravenous Infusion in Healthy Subjects
Latest Information Update: 22 Dec 2023
At a glance
- Drugs STSA-1002 (Primary)
- Indications SARS-CoV-2 acute respiratory disease; Vasculitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Staidson Beijing BioPharmaceuticals
- 13 Apr 2023 Status changed from recruiting to completed.
- 12 Jan 2022 Status changed from not yet recruiting to recruiting.
- 30 Dec 2021 New trial record